Additionally, techniques such as CRISPR/Cas9-mediated gene editing or electroporation-based siRNA loading (e.g., targeting TGF-β1) hold considerable potential for anti-fibrotic treatments in chronic kidney disease. This evidence concerns the gene TGFB1 and chronic kidney disease.